“…• Access to clinical, molecular diagnostic testing for TTR mutations, as lack of access to testing may hinder prior/ initial authorization for pharmacogenomic treatment for health-compromised patients with hATTR (Blue Cross Blue Shield, 2019; Cigna, 2023;UnitedHealthcare, 2023) A/AA/AC nursing professionals, who often spend time at the bedside learning patients' stories and experiences to document such information within electronic health records, and other health system stakeholders consider patient community stories as powerful resources to directly address health disparities through intentional data collection, use, and reporting (Hendricks-Sturrup, 2021;Evidation, n.d.). Moreover, A/AA/AC nursing professionals, in addition to caregivers of A/AA/ AC patients with AL and ATTR amyloidosis, are well-positioned to inform the development of both objective and subjective PROs (i.e., PROMIS ® , PRO-CTCAE, ATTR-QOL, interviews and focus groups) intended to capture the AL and ATTR A/AA/AC patient experience within the electronic health record.…”